Overview

A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma

Status:
Completed

Trial end date:
2019-04-24

Target enrollment:

Participant gender:

Summary

This study is for adult subjects with advanced tissue sarcoma. The study involves the drugs Pazopanib (Votrient), Gemcitabine (Gemzar), and Docetaxel (Taxotere). The purpose of this study is to test the effectiveness and safety of Gemcitabine and Pazopanib compared with Gemcitabine and Docetaxel in participants with soft tissue sarcoma.

Phase:

Phase 2

Details

Lead Sponsor:

Medical University of South Carolina

Collaborator:

Novartis

Treatments:

Docetaxel
Gemcitabine